The process also successfully separated the EPI, DOX, and DOL from clinical plasma samples collected from patients undergoing chemotherapy treatment with DOX as shown in Figure . TLC plates from two different patients are shown. The use of actual clinical samples is critical when evaluating a new bioanalytical method. Cancer patient plasma samples can have more debris and contaminates than healthy patient samples used for spiking. These contaminates affect quantification, but this method has been successful in separating the contaminates from the drugs to a degree that allows for accurate quantification of the drug concentration.